We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Fujifilm

Offers diagnostic imaging products, including FCR” digital x-ray imaging and diagnostic systems, “Synapse” medical-us... read more Featured Products: More products

Download Mobile App





Fujifilm Showcases DRI-CHEM NX700 Dry Chemistry Analyzer

By LabMedica International staff writers
Posted on 07 Feb 2018
Print article
The DRI-CHEM NX700 dry chemistry analyzer (Photo courtesy of Fujifilm).
The DRI-CHEM NX700 dry chemistry analyzer (Photo courtesy of Fujifilm).
Fujifilm Corporation (Tokyo, Japan) showcased its new generation dry chemistry analyzer series, DRI-CHEM NX700, which can perform multiple test parameters of clinical chemistry, at MEDLAB Middle East 2018.
 
Fujifilm is a pioneer in diagnostic imaging and information systems for healthcare facilities and also provides Point-of-Care Testing products for healthcare providers who need immediate clinical test results. At MEDLAB Middle East 2018, the world’s largest attended laboratory & IVD exhibition and conference held in Dubai, UAE from February 5-8, 2018, Fujifilm showcased its DRI-CHEM NX700 dry chemistry analyzer series which offers a high processing speed of 190 tests per hour and makes it possible to set five samples at the same time.
 
Equipped with STAT functionality to accommodate emergency interrupt measurement, the DRI-CHEM NX700 does not require pre-treatment of sample or calibration using the QC card system. It offers easy operations with a touch screen and intuitive new software, along with enhanced connectivity features and HL7 support. The DRI-CHEM NX700 dry chemistry analyzer series is patient-friendly as it requires a testing microsample of only 6 μL and 10 μL per test. Featuring a new design with a compact size and smaller foot print, it allows for the use of different range of sample tubes.
 
Gold Supplier
COVID-19 NAb Test Solution
COVID-19 NAb Test Solution
New
SARS-CoV-2 IgG Antibodies Anti-S1 Assay
iRapid SARS-CoV-2 Quant "Neutralizing" Ab
New
5-Part Hematology Analyzer
Cellcount-60
New
Chemiluminescence Analyzer
DZ-Lite 3000 Plus

Print article

Channels

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.